A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Eli Lilly and Company
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Mayo Clinic
Pfizer
Tizona Therapeutics, Inc
UNC Lineberger Comprehensive Cancer Center
Eli Lilly and Company
Novartis
TILT Biotherapeutics Ltd.
Institute of Cancer Research, United Kingdom
Memorial Sloan Kettering Cancer Center
Incyte Corporation
Trishula Therapeutics, Inc.
M.D. Anderson Cancer Center
Compugen Ltd
Thomas Jefferson University
Inspirna, Inc.
Jonsson Comprehensive Cancer Center
Inhibrx Biosciences, Inc
National Cancer Institute (NCI)
Coherus Oncology, Inc.
Celldex Therapeutics
University of California, San Francisco
Wellmarker Bio
R-Pharm
Corvus Pharmaceuticals, Inc.
Memorial Sloan Kettering Cancer Center
Cantargia AB
M.D. Anderson Cancer Center
Viralytics
Incyte Corporation
Syndax Pharmaceuticals
BioNTech SE
Pfizer